EMA will review tepotinib as a treatment for adult patients with advanced non-small cell lung cancer. Credit: Merck KGaA.

The European Medicines Agency (EMA) has validated Merck’s application for reviewing tepotinib as a treatment for adult patients with advanced non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition factor gene (MET) exon 14 (METex14) skipping alterations.

The EMA will now initiate the review process as the application is complete with the validation.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Administered once daily, tepotinib is a highly selective oral MET inhibitor.

Discovered and developed by Merck, it has a highly selective mechanism of action and can potentially improve outcomes in aggressive tumours.

The application submitted to EMA comes from primary analysis data from the pivotal Phase II VISION study.

The trial is analysing tepotinib as monotherapy in patients with advanced NSCLC with METex14 skipping alterations, prospectively assessed by liquid biopsy (LBx) or tissue biopsy (TBx).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In the ongoing study, the patient population has a median age of 74 years, characterised as elderly, with poor clinical prognosis typical of NSCLC with METex14 skipping alterations.

In March, Japan approved tepotinib through the SAKIGAKE programme thus making it the first oral MET inhibitor indicated for treating advanced NSCLC harbouring MET gene alterations to receive regulatory approval.

The US Food and Drug Administration (FDA) also granted orphan drug designation to tepotinib.

FDA is also reviewing the application under priority review and through the real-time oncology review pilot programme.

Furthermore, tepotinib plus osimertinib is being evaluated in the Phase II INSIGHT 2 study in MET amplified, advanced or metastatic NSCLC harbouring activating EGFR mutations.

In the Phase II PERSPECTIVE study, the MET inhibitor in combination with cetuximab is being assessed in RAS / BRAF wild-type left-sided metastatic colorectal cancer patients.